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e have demonstrated previously that adult human
synovial membrane-derived mesenchymal stem
cells (hSM-MSCs) have myogenic potential in
vitro (De Bari, C., F. Dell’Accio, P. Tylzanowski, and F.P.
Luyten. 2001. 
 
Arthritis Rheum.
 
 44:1928–1942). In the present
study, we have characterized their myogenic differentiation
in a nude mouse model of skeletal muscle regeneration
and provide proof of principle of their potential use for
muscle repair in the mdx mouse model of Duchenne
muscular dystrophy. When implanted into regenerating
nude mouse muscle, hSM-MSCs contributed to myoﬁbers
and to long term persisting functional satellite cells. No
W
 
nuclear fusion hybrids were observed between donor human
cells and host mouse muscle cells. Myogenic differentiation
proceeded through a molecular cascade resembling embry-
onic muscle development. Differentiation was sensitive to
environmental cues, since hSM-MSCs injected into the blood-
stream engrafted in several tissues, but acquired the muscle
phenotype only within skeletal muscle. When administered
into dystrophic muscles of immunosuppressed mdx mice,
hSM-MSCs restored sarcolemmal expression of dystrophin,
reduced central nucleation, and rescued the expression of
mouse mechano growth factor.
 
Introduction
 
Skeletal muscle consists predominantly of syncytial fibers
with peripheral, postmitotic myonuclei. Its intrinsic repair
potential in adulthood relies on the persistence of a resident
reserve population of undifferentiated mononuclear cells,
termed satellite cells. In mature skeletal muscle, most satellite
cells are quiescent and are activated in response to environ-
mental cues such as injury to mediate postnatal muscle regener-
ation. After division, satellite cell progeny, termed myoblasts,
undergo terminal differentiation and become incorporated
into muscle fibers (Bischoff, 1994).
Myogenesis is regulated by a family of transcription factors
(myogenic regulatory factors [MRFs]*), including MyoD,
Myf5, myogenin, and MRF4 (Sabourin and Rudnicki,
2000). During embryonic development, MyoD and Myf5
are involved in the establishment of the skeletal muscle lineage
(Rudnicki et al., 1993), whereas myogenin is required for
terminal differentiation (Hasty et al., 1993; Nabeshima et
al., 1993). During muscle repair, satellite cells recapitulate
the MRF expression program manifested during embryonic
development. Quiescent satellite cells do not express detectable
levels of MRFs. After muscle injury, they proliferate and express
Myf5 and MyoD (Cornelison and Wold, 1997; Cooper et
al., 1999). Myogenin is expressed later and is associated with
fusion and terminal differentiation (Smith et al., 1994;
Yablonka-Reuveni and Rivera, 1994).
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centromere 18; CMV, cytomegalovirus; CN, centronucleated; CTX,
cardiotoxin; DMD, Duchenne muscular dystrophy; ET, electrotransfer;
hSM-MSC, human synovial membrane-derived mesenchymal stem cell;
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stem cell; MyHC-IIx/d, myosin heavy chain type IIx/d; PCNA, proliferating
cell nuclear antigen; Q, quantitative; pCMV-dystrophin, plasmid DNA
containing human dystrophin under the CMV promoter; SM, synovial
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Duchenne muscular dystrophy (DMD), the most com-
mon lethal genetic disorder in children, is an X-linked reces-
sive muscle disease characterized by the absence of dystro-
phin at the sarcolemma of muscle fibers (Hoffman et al.,
1987). Dystrophin is associated with a large oligomeric com-
plex of glycoproteins called dystrophin-associated proteins,
which provide linkage to the extracellular membrane (Ervasti
and Campbell, 1991). The absence of dystrophin results in
destabilization of the extracellular membrane–sarcolemma-
cytoskeleton architecture, making muscle fibers susceptible
to contraction-associated mechanical stress and degenera-
tion. In the first phase of the disease, new muscle fibers are
formed by satellite cells. After depletion of the satellite cell
pool in childhood, skeletal muscles degenerate progressively
and irreversibly and are replaced by fibrotic tissue (Cossu
and Mavilio, 2000). Like DMD patients, the mdx mouse
lacks dystrophin in skeletal muscle fibers (Hoffman et al.,
1987; Sicinski et al., 1989). However, the mdx mouse devel-
ops a mild dystrophic phenotype, probably because muscle
regeneration by satellite cells is efficient for most of the ani-
mal’s life span (Cossu and Mavilio, 2000). The lack of dys-
trophin is associated with secondary dysregulation of molec-
ular pathways possibly involved in muscle regeneration.
Mechano growth factor (MGF) is a splice variant of insulin-
like growth factor-I expressed by skeletal myofibers and up-
regulated in response to mechanical stimulation (Yang et al.,
1996). MGF is an autocrine/paracrine growth factor that ap-
pears to play a role in local muscle maintenance and repair
(Yang et al., 1996; Goldspink, 1999). It was reported that
MGF mRNA is not detectable in dystrophic mdx muscles
even when subjected to mechanical stimulation (Goldspink,
1999; Yang and Goldspink, 2002). This is likely to contrib-
ute to the muscle impairment in the mdx mouse.
Myoblasts represent the natural first choice in cellular
therapeutics for skeletal muscle because of their intrinsic
myogenic commitment (Grounds et al., 2002). However,
myoblasts are recovered in low number from DMD muscle
biopsies, are poorly expandable in vitro, and rapidly undergo
senescence (Cossu and Mavilio, 2000). An alternative source
of muscle progenitor cells is desirable. We have reported re-
cently the isolation and characterization of mesenchymal
stem cells (MSCs) from the synovial membrane (SM) of
adult human donors (De Bari et al., 2001). Human synovial
membrane-derived MSCs (hSM-MSCs) are easily expand-
able in culture, maintain a stable molecular profile, and re-
tain multipotentiality in vitro over at least 10 passages (De
Bari et al., 2001). In the present work, we have characterized
the myogenic differentiation of hSM-MSCs in an in vivo
model of skeletal muscle regeneration and provide evidence
of their capacity to partially restore specific pathophysiologic
features of the dystrophic muscle in the mdx mouse model
of DMD.
Figure 1. Contribution of hSM-MSCs to skeletal 
muscle regeneration in vivo. (A and B) Localization 
of the human nuclei within the mouse skeletal 
muscle. (A) ISH for human Alu repeats on a 
representative longitudinal cryosection from a 
nude mouse TA muscle at 4 wk after hSM-MSC 
transplantation. Human nuclei are stained black. 
In B, brightfield and fluorescence (DAPI counter-
staining) images were given artificial colors and 
superimposed. The Alu-positive nuclei are shown 
in red, and the Alu-negative, DAPI-stained nuclei 
are shown in green. Bar, 200  m. (C) X-gal staining 
with hematoxylin-eosin counterstaining at 3 wk 
after transplantation of hSM-MSCs transduced with 
AdCMV-LacZ. Arrows point to muscle fibers with 
diffuse  -gal expression. Bar, 50  m. (D) Immuno-
histochemistry for human  2M (brown). Nuclei are 
counterstained with hematoxylin (blue). Bar, 20  m. 
(E) SQ–RT-PCR for human MyHC-IIx/d. CTX-
treated TA muscle was injected with either human 
keratinocytes (lane 2) or hSM-MSCs (lane 3); CTX-
treated muscle injected with PBS was used as 
tissue-negative control (lane 1). Lane 4, RT-negative 
control of lane 3; lane 5, human skeletal muscle 
(h-SkM) as a positive control. cDNAs were equalized 
for the expression of human  -actin. At 3 wk after 
transplantation, human MyHC-IIx/d was detected 
only in the muscle injected with SM-MSCs. 
(F) Double genomic FISH on a cryosection from a 
TA muscle at 4 wk after hSM-MSC transplantation 
using a probe for human CEN18 (green) and a 
probe for mouse centromeric satellite DNA (red). 
Nuclei were counterstained with DAPI (blue). 
Arrows point to human nuclei. Bar, 50  m.T
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Results
 
Contribution to myofibers
 
To study myogenic differentiation of hSM-MSCs in vivo,
we adopted a well-defined mouse model of skeletal muscle
regeneration. The model consists of injuring the tibialis an-
terior (TA) muscle by injecting cardiotoxin (CTX). 24 h
later, culture-expanded hSM-MSCs were injected into the
same TA muscle. Nude mice were chosen to avoid rejection
of the human cells.
To localize the injected human cells, we chose to trace the
nuclei, which preserve their individuality within syncytial fi-
bers, by using in situ hybridization (ISH) for human Alu ge-
nomic repeats. At 4 wk after transplantation, 60% (109 out
of 180) of the stained longitudinal serial sections throughout
the mouse TA muscle contained human nuclei (87 
 
 
 
 45 per
section, mean 
 
 
 
 SD, range 3–285) (Fig. 1, A and B). To in-
vestigate the integration of human cells into muscle fibers,
we followed two strategies. First, we implanted into regener-
ating TA muscles hSM-MSCs transduced with an adeno-
virus containing the 
 
LacZ
 
 gene under the transcriptional
control of the cytomegalovirus (CMV) promoter (AdCMV-
 
LacZ
 
). At 1 wk, bacterial 
 
 
 
-galactosidase (
 
 
 
-gal) was de-
tected in mononuclear cells but not in myofibers (unpub-
lished data). At 3 wk, some myofibers displayed diffuse
 
 
 
-gal expression (Fig. 1 C), demonstrating incorporation of
at least one transduced human cell for each 
 
 
 
-gal–positive fi-
ber. The second strategy consisted of staining sections of TA
muscles for human 
 
 
 
2-microglobulin (
 
 
 
2M). After 3 wk,
some fibers displayed sarcolemmal expression of human
 
 
 
2M in the TA muscle injected with hSM-MSCs (Fig. 1
D). The detection of human 
 
 
 
2M at the sarcolemma of
muscle fibers represents indirect evidence that each human-
 
 
 
2M–positive fiber was contributed by at least one hSM-
MSC. The muscle fibers contributed by human cells were
mostly located in regenerating areas as suggested by the het-
erogeneous size of the myofibers and the central location of
their myonuclei (Gillis, 1999).
To determine whether the human cells implanted in the
mouse TA muscles acquired the skeletal muscle phenotype,
we used RT-PCR with primers specific for human cDNAs.
At 3 wk, we detected human myosin heavy chain type IIx/d
(MyHC-IIx/d) in the TA muscles injected with hSM-
MSCs. Under similar experimental conditions, we did not
detect human muscle markers in the TA muscles injected
with human keratinocytes, although human 
 
 
 
-actin was de-
tectable (Fig. 1 E).
Cell nuclear fusion has been suggested recently as a possi-
ble explanation for apparent stem cell plasticity (Terada et
al., 2002; Ying et al., 2002). To investigate the occurrence of
fusion hybrids between donor hSM-MSC nuclei and recipi-
ent mouse muscle nuclei, we performed double FISH using
a probe for human centromere 18 (CEN18) and a probe for
mouse centromeric satellite DNA on sections of TA muscles
4 wk after hSM-MSC transplantation (Fig. 1 F). Over 160
human nuclei counted in two longitudinal sections, 154
(96%) were distinct from mouse nuclei. The remaining six
human nuclei were located in areas where mouse and human
nuclei were clustered, making it impossible to distinguish
between overlapping or fused nuclei (unpublished data). To-
gether, these findings provide evidence that implanted hSM-
MSCs can fuse with host myofibers and contribute their ge-
netic information to the mosaic fibers generated. The detec-
tion of human MyHC-IIx/d suggests that some human cells
acquired the skeletal muscle phenotype. Contribution to
muscle regeneration was reproducible regardless of cell stor-
age in liquid nitrogen or donor age within the ranges exam-
ined and was inherent to individual cell clones of multipo-
tent SM-MSCs (Fig. S1 available at http://www.jcb.org/cgi/
content/full/jcb.200212064/DC1).
 
SM-MSC differentiation recapitulates 
embryonic myogenesis
 
To test the hypothesis that the mature skeletal muscle phe-
notype of the human cells was acquired through a cascade of
molecular events reminiscent of embryonic myogenesis, we
analyzed expression of muscle differentiation genes at several
time points by semiquantitative (SQ) RT-PCR using prim-
Figure 2. Muscle differentiation of hSM-MSCs recapitulates 
embryonic myogenesis. (A) hSM-MSCs were injected into regenerating 
(CTX-treated) TA muscles of nude mice. Mice were killed at different 
time points as indicated. The dissected muscles were subjected to 
SQ–RT-PCR analysis. TA muscles containing human cells were 
equalized for the expression of human  -actin. TA muscles with no 
human cells served as controls for species specificity of the primers 
for human cDNAs. For each time point, a PBS-injected regenerating 
(CTX-treated) mouse TA muscle was included for a negative control. 
m-TA, uninjected mouse TA muscle; m-CTX-TA, mouse CTX-treated 
TA muscle. (B) Number of human CE per TA muscle over time as 
determined by Q–RT-PCR (see Results for details).T
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ers specific for human cDNAs. We observed an early peak of
human Myf5 and proliferating cell nuclear antigen (PCNA)
at 24 h after cell implantation. With the decline of Myf5,
the expression of human myogenin increased, peaking at
8 d, and then decreased, whereas markers of mature muscle,
such as MyHC, muscle creatine kinase, and dystrophin, pro-
gressively reached plateau levels (Fig. 2 A). These data indi-
cate that muscle differentiation of hSM-MSCs, in this
model, appears to recapitulate embryonic muscle formation.
The proliferation, suggested by high levels of PCNA, paral-
leled an increase in the expression of human 
 
 
 
-actin per
TA muscle over time (Fig. 2 B). The expression of human
 
 
 
-actin was considered indicative of the number of human
cells or, since some human cells fused with myofibers, hu-
man “cell equivalents” (CE) per TA muscle. Values are ex-
pressed as the total number of human CE per TA muscle.
They were obtained by performing a regression analysis of
the ratio of human 
 
 
 
-actin to mouse/human 
 
 
 
-actin using a
standard curve generated by injecting from 2.5 million to 30
hSM-MSCs (unpublished data). The experimental values
were within the linear range of the curve.
 
Differentiation is sensitive to environmental cues
 
Systemic delivery is an attractive route of administration of
cells to target tissue and organ systems. We tested whether
hSM-MSCs preferentially home to damaged skeletal muscle
and contribute to muscle regeneration when delivered sys-
temically. We administered 5 
 
 
 
 10
 
6
 
 hSM-MSCs in the tail
vein of six mice, which had received a CTX injection into
one TA muscle 24 h earlier. Two animals were killed at
each time point examined, up to 6 mo. hSM-MSCs homed
preferentially to the CTX-injured TA muscle. However, the
number of human CE, initially not detected in the unin-
jured muscle, increased progressively over time in both TA
muscles, remaining constantly higher in the CTX-injured
muscle (Fig. 3 A). At 6 mo, we detected human MyHC-IIx/d
in both CTX-treated and -untreated TA muscles (Fig. 3 B)
and localized human nuclei by ISH for human Alu ge-
nomic repeats (Fig. 3 C). We do not report expression of
human MyHC-IIx/d at 3 and 8 wk because at these time
points the numbers of human CE in TA muscles were too
low for a reliable estimation of its expression levels. At 6
mo, the CTX-induced muscle injury did not influence the
expression of human MyHC-IIx/d normalized for human
 
 
 
-actin (Fig. 3 B), as in the experiments performed with
local implantation of hSM-MSCs at 3 mo (Fig. S2 avail-
able at http://www.jcb.org/cgi/content/full/jcb.200212064/
DC1). Although, as determined by RT-PCR for human
 
 
 
-actin and/or ISH for human Alu repeats, human cells were
also found in other mouse tissues and organs such as lungs,
we have been unable to detect expression of human MyHC-
IIx/d and muscle creatine kinase in tissues other than skele-
tal muscle at any of the time points examined (Fig. 3 B).
Together, these results suggest that hSM-MSCs engrafted
into skeletal muscle after systemic administration, with
preferential homing to the damaged muscle and long-term
contribution to muscle regeneration. The expression of hu-
man MyHC-IIx/d was specific to skeletal muscle with no
apparent heterotopic muscle formation, suggesting a con-
text-sensitive differentiation response of the hSM-MSCs.
We have never observed any adverse effect(s), such as ec-
topic tissue formation or tumor development, after injec-
tion in nude mice of hSM-MSCs even at high doses (2 
 
 
 
10
 
7
 
 cells) regardless of the site and the route of administra-
tion (Fig. S2).
 
Contribution to functional satellite cells
 
Satellite cells are mononucleated cells located between the
sarcolemma and the basal lamina of the muscle fibers (Bis-
choff, 1994) and are considered the muscle-specific stem
cells (LaBarge and Blau, 2002). To test the possibility that
some of the implanted human cells contributed to the satel-
lite cell compartment, we performed double immunostain-
ing for laminin, which identifies the basal lamina, and hu-
Figure 3. Differentiation is sensitive to environmental 
cues. (A) Preferential homing to the damaged skeletal 
muscle of systemically delivered hSM-MSCs. As 
determined by Q–RT-PCR, the number of human CE 
increased in parallel over time in both CTX-injured 
and uninjured host TA muscles, remaining constantly 
higher in the CTX-injured muscles. Two mice were 
killed at each time point examined with similar results. 
(B) SQ–RT-PCR analysis at the 6 mo time point. cDNAs 
were equalized for the expression of mouse/human 
 -actin. Human MyHC-IIx/d was detected in both the 
CTX-treated and -untreated TA muscles (lanes 2 and 
3). Lungs (lane 4) expressed human  -actin at levels at 
least comparable to TA muscles, but MyHC-IIx/d was 
not detectable. Controls were mouse TA muscle (lane 
1) and RT-negative control of lane 2 (lane 5). (C) ISH 
for human Alu repeats on a longitudinal section from 
a TA muscle at 6 mo after systemic administration of 
hSM-MSCs. Counterstaining with eosin. Bar, 50  m.T
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man 
 
 
 
2M, which labels the human cells, on sections of TA
muscles 6 mo after human SM-MSC transplantation. We
detected human-
 
 
 
2M–positive mononuclear cells residing
between basal lamina and muscle fibers (Fig. 4 A). The
staining for human 
 
 
 
2M did not extend to the sarcolemma
of the adjacent myofibers, indicating that the human cells
had not fused with mouse muscle fibers. Given the absence
of specific markers, EM is the most reliable way to identify
satellite cells (Grounds et al., 2002). We analyzed sections of
TA muscles of nude mice transplanted 6 mo earlier with
hSM-MSCs by transmission electron microscopy (TEM),
after staining for human 
 
 
 
2M. Some mononuclear cells that
fulfilled the ultrastructural criteria of satellite cells (Bischoff,
1994) displayed staining for human 
 
 
 
2M that was associ-
ated with the plasma membrane (Fig. 4 B). These results
demonstrate that a subpopulation of the implanted hSM-
MSCs can persist for at least 6 mo as satellite cells.
Quiescent (Myf5-negative) satellite cells respond to mus-
cle injury with proliferation and expression of activation
markers, such as Myf5 (Cornelison and Wold, 1997; Coo-
per et al., 1999). To test whether the engrafted hSM-MSCs
contributed long term functional satellite cells, we injected
CTX to injure the right TA muscles of three mice that 6 mo
earlier had received hSM-MSCs bilaterally into regenerat-
ing TA muscles. Contralateral TA muscles received PBS.
After 12 h, SQ–RT-PCR revealed high expression levels of
human PCNA and Myf5 in the CTX-injured TA muscles
compared with the CTX-untreated contralateral muscles
(Fig. 4 C), indicating that human cells transplanted 6 mo
earlier persisted within the regenerated muscle as quiescent
(Myf5-negative) satellite cells and were capable of activation
upon injury.
Satellite cells are known to be able to form myotubes un-
der low serum conditions in vitro and to contribute to mus-
cle repair when injected into a regenerating muscle in vivo
(Seale and Rudnicki, 2000). To investigate whether the
hSM-MSC–derived satellite cells displayed similar proper-
ties, we established cultures of primary myoblasts derived
from satellite cells (Zammit and Beauchamp, 2001) from
mouse TA muscles that had been injected with hSM-MSCs
6 mo earlier (first recipients). During in vitro expansion,
human cell nuclei remained distinct from mouse cell nuclei
with no apparent fusion as determined by double genomic
FISH (unpublished data). As reported with primary myo-
blasts (Smith et al., 1994; Cornelison and Wold, 1997), in
our cultures of first recipient primary myoblasts we detected
human Myf5 but not terminal differentiation markers such
as human MyHC-IIx/d (Fig. 4 D). Under low serum
conditions, cells underwent terminal differentiation and
formed multinucleated myotubes that expressed human
MyHC (unpublished data). This property was not shared
by hSM-MSCs before implantation in the first recipients
(unpublished data). At 
 
 
 
70% confluence, the first recipi-
ent primary myoblasts were implanted into regenerating
TA muscles of second recipient mice. 1 mo later, we de-
tected human MyHC-IIx/d (Fig. 4 D), indicating that re-
covered human cells contributed to muscle regeneration in
second recipients.
Figure 4. Contribution to functional satellite cells. 
(A) Double IF staining for laminin (red) and human 
 2M (green) at 6 mo after hSM-MSC transplantation 
into mouse TA muscle. The nuclei were revealed by 
DAPI staining (blue). A mononuclear cell staining 
positive for human  2M (arrowhead) is shown 
between the laminin-positive basal lamina and a 
distinct ( 2M-negative) myofiber. The arrow points 
to another mononuclear cell of human origin lying 
outside of the basal lamina. Bar, 50  m. (B) TEM of 
a hSM-MSC–derived satellite cell at 6 mo after 
hSM-MSC transplantation. The high magnification 
(bar, 1  m) of a satellite cell shows a plasma 
membrane positive for human  2M (white arrows), 
separating the satellite cell from its adjacent  2M-
negative myofiber, the continuous basal lamina 
(black arrow) surrounding the satellite cell and 
myofiber, and the heterochromatic appearance of 
the nucleus. Inset shows an inverted, magnified 
view of the staining for human  2M. (C) Satellite 
cell-like response of hSM-MSCs in vivo upon 
muscle injury. 6 mo after hSM-MSC bilateral 
implantation into regenerating TA muscles, CTX 
was injected into the right TA muscle and PBS into 
the contralateral muscle. Animals were killed 12 h 
later. SQ–RT-PCR analysis was performed after equalization of cDNAs for human  -actin. High levels of human Myf5 and human PCNA 
were observed in the CTX-treated TA muscle (lane 4) compared with the contralateral muscle (lane 5), indicating the presence of hSM-MSC–
derived functional satellite cells. The following were controls: mouse TA muscle (lane 1); mouse TA muscle at 12 h after CTX treatment (lane 
2); mouse CTX-treated TA muscle implanted with hSM-MSCs and harvested after 6 mo as external control (lane 3); and RT-negative control 
of lane 4 (lane 6). (D) Human mononuclear cells recovered from first recipient mice retain in vivo myogenic activity when transplanted into 
a second recipient. 6 mo after hSM-MSC transplantation, first recipient mice were killed, and cultures of primary myoblasts were established 
from the injected TA muscles. At 70% confluence, these cells were injected into regenerating TA muscles of second recipient mice, which 
were killed 1 mo later. Lane 1, control mouse TA muscle; lane 2, TA muscle from first mouse recipient; lane 3, first recipient primary myoblasts; 
lane 4, TA muscle from second mouse recipient; lane 5, RT-negative control of lane 4.T
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Partial restoration of muscle pathology in mdx mice
 
To explore whether hSM-MSCs can correct the genetic
muscle disorder of the mdx mouse, we transplanted hSM-
MSCs into the right TA muscles of three immunosup-
pressed mdx mice. The left TA muscles were injected with
PBS as internal controls. After 4 wk, mdx TA muscles in-
jected with hSM-MSCs expressed human dystrophin and
MyHC-IIx/d, whereas the contralateral PBS-injected TA
muscles did not (Fig. 5 A). To localize human dystrophin
protein, we performed an immunostaining using an anti-
body that does not react with mouse dystrophin (Huard et
al., 1993). Therefore, putative revertant fibers expressing
dystrophin protein (Lu et al., 2000) would not be detected
(Braun et al., 2000). In hSM-MSC–injected mdx TA mus-
cles, we observed clusters of myofibers with peripheral hu-
man-dystrophin immunoreactivity (Fig. 5 B). Human nu-
clei were detected in a parallel, nonconsecutive section in an
area corresponding to the location of human-dystrophin–
positive myofibers (Fig. 5 C).
The percentage of centronucleated (CN) myofibers is in-
dicative of previous cycles of degeneration and regeneration
and is inversely correlated with the ability of dystrophin to
protect muscle fibers from these cycles (Gillis, 1999). In
hSM-MSC–injected mdx TA muscles, the percentage of
CN human-dystrophin–positive fibers was significantly
lower than the contralateral PBS-injected TA muscle fi-
bers counted after hematoxylin-eosin staining (hSM-MSCs,
53.1% 
 
 
 
 5.2 versus PBS, 71.0% 
 
 
 
 1.6; P 
 
  
 
0.05) (Fig. 5
D). Together, these data indicate that transplantation of
hSM-MSCs into dystrophic mdx muscle is associated with
restoration of sarcolemmal expression of dystrophin and re-
duction of the central nucleation.
 
Partial rescue of mouse MGF in mdx muscle
 
Dysregulation of MGF expression has been described in
mdx muscle. In particular, MGF was not detected by RT-
PCR (Goldspink, 1999; Yang and Goldspink, 2002). Com-
pared with PBS-injected contralateral TA muscles, we ob-
served a reproducible partial restoration of mouse-specific
MGF mRNA at 4 wk after hSM-MSC transplantation (Fig.
6 A). For comparison, we injected a plasmid DNA con-
taining full-length human dystrophin (pCMV-dystrophin;
Braun et al., 2000) into TA muscles of three immunosup-
pressed mdx mice. To increase the efficacy of in vivo trans-
duction, electrotransfer (ET) was applied after plasmid
DNA injection in additional three mice. After 4 wk, sar-
colemmal expression of human dystrophin was detected by
immunostaining in transverse sections from all pCMV-dys-
trophin–injected TA muscles (unpublished data). The max-
imal number of human-dystrophin–positive fibers per trans-
verse section was 69.3 
 
 
 
 10.3 in TA muscles injected with
hSM-MSCs, 42.0 
 
 
 
 7.9 in TA muscles injected with
pCMV-dystrophin, and 275.0 
 
 
 
 81.2 when ET was ap-
plied (Fig. 6 B). We observed no significant difference in
the percentage of CN human-dystrophin–positive myo-
fibers (hSM-MSCs, 53.1% 
 
 
 
 5.2, pCMV-dystrophin,
50.4% 
 
 
 
 4.9, pCMV-dystrophin ET, 47.3 
 
 
 
 6.6) (Fig. 6
C). However, the expression levels of mouse MGF, as deter-
mined by quantitative (Q) RT-PCR, remained low in all
pCMV-dystrophin–injected muscles, analogous to the PBS-
injected or pCMV-
 
LacZ
 
–injected mdx muscles (Fig. 6 D).
On longitudinal sections, dystrophin immunostaining was
segmental in both SM-MSC–injected and pCMV-dystro-
phin–injected mdx TA muscles, extending over 
 
 
 
100–700
 
 
 
m (unpublished data), which reflects the dystrophin nu-
clear domain reported in previous studies (Gussoni et al.,
1997; Vilquin et al., 2001).
 
Discussion
 
We have described previously the isolation and characteriza-
tion in vitro of MSCs from adult human SM (De Bari et al.,
2001). In the present study, we report that hSM-MSCs can
participate in skeletal muscle regeneration in vivo by long
term persistence and contribution to both myofibers and
functional satellite cells. In addition, we provide evidence
Figure 5. Restoration of dystrophin in mdx 
muscle fibers by hSM-MSCs. (A) SQ–RT-PCR for 
human dystrophin. cDNAs were equalized for 
mouse/human  -actin expression. In all mdx mice, 
TA muscles injected with hSM-MSCs expressed 
human dystrophin and human MyHC-IIx/d, whereas 
the contralateral muscles did not. (B) IF staining for 
human dystrophin (red) of a TA muscle transverse 
cryosection from an mdx mouse at 4 wk after 
hSM-MSC transplantation. Nuclei are shown in 
green. Clusters of muscle fibers display peripheral 
localization of the human dystrophin protein. Bar, 
100  m. (C) ISH for human Alu repeats on a parallel, 
nonconsecutive section, showing human nuclei in 
the squared area of (B). Counterstaining with eosin. 
Bar, 100  m. (D) The percentage of CN human-
dystrophin–positive fibers was significantly lower 
in the hSM-MSC–injected TA muscles than in the 
contralateral PBS-injected TA muscle fibers in 
three mdx mice (P   0.05).T
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that hSM-MSCs can partially restore muscle pathophysiol-
ogy in mdx mice.
 
The identity of human SM-MSCs
 
A recent report (Gerhart et al., 2001) showed that MyoD-
positive cells were present in many fetal chick organs and
that these cells differentiated into skeletal muscle in culture.
Whether similar committed myogenic cells are resident in
postnatal tissues and organs in humans, and in particular in
SM, remains to be determined. Nevertheless, we were un-
able to detect expression of MRFs in either human synovial
tissue or SM-MSCs in vitro by RT-PCR.
Bone marrow (BM) is known to contain two types of stem
cells, the hematopoietic stem cells and the MSCs, both dis-
playing myogenic potential (Ferrari et al., 1998) and both
circulating in the bloodstream (Kuznetsov et al., 2001;
Wright et al., 2001). SM-MSCs are indeed similar to BM-
MSCs in their behavior in vitro. Like BM-MSCs (Prockop,
1997; Pittenger et al., 1999), SM-MSCs rapidly adhere to
plastic and can be expanded for several passages, preserving
their molecular profile and multipotentiality (De Bari et
al., 2001). These characteristics make MSCs, irrespective
of their origin, distinct from hematopoietic stem cells
(Prockop, 1997; Pittenger et al., 1999). Whether the SM-
MSCs are derived from endogenous resident cells or origi-
nate from circulating MSCs (Kuznetsov et al., 2001) is de-
batable. Increasing evidence suggests that MSCs isolated
from different tissues and organs would have different phe-
notypic and biological traits in vitro and in vivo (Kuznetsov
et al., 2001; unpublished data). However, manipulations,
such as tissue dissection, cell isolation, and subsequent cul-
ture expansion, can profoundly influence patterns of gene
expression and differentiation potentials.
Recently, it has been demonstrated that postnatal BM
contains primitive progenitors termed multipotent adult
progenitor cells, which copurify with MSCs (Jiang et al.,
2002). We cannot exclude that our hSM-MSCs also contain
a subpopulation of these progenitors.
 
Muscle differentiation of hSM-MSCs recapitulates 
embryonic myogenesis
 
Expression by hSM-MSCs of muscle-specific genes does not
appear to be the consequence of reprogramming of human
nuclei secondary to fusion into host muscle fibers (Blau et
al., 1985). First, some hSM-MSCs can differentiate in vitro
to form MyHC-positive multinucleated myotubes (De Bari
et al., 2001), demonstrating that fusion with muscle cells is
not required for myogenesis. Second, we have documented
immediate-early muscle-specific differentiation events hap-
pening and even extinguishing before fusion with myofibers
could be proven. Although we cannot exclude sporadic early
fusion with host muscle fibers, under our experimental con-
ditions we did not detect muscle fibers contributed by hu-
man cells before 7 d. In contrast, we observed a peak of hu-
man Myf5 as early as 24 h after hSM-MSC transplantation.
During embryonic development, Myf5 is necessary to re-
strict undifferentiated cells to myogenesis (Tajbakhsh et al.,
1996). The subsequent decrease in Myf5 expression coin-
cided with the peak of myogenin at 8 d followed by plateau
levels of mature muscle markers. It is known that myogenin
expression occurs during fusion and terminal differentiation
(Hasty et al., 1993; Nabeshima et al., 1993; Smith et al.,
Figure 6. Rescue of mouse MGF in mdx muscle by 
hSM-MSCs. (A) SQ–RT-PCR for mouse MGF. cDNAs 
were equalized for mouse/human  -actin expression. 
In the first lane, human skeletal muscle was added for 
mouse primer specificity. Mouse MGF expression was 
reproducibly restored in the mdx TA muscles injected 
with hSM-MSCs to levels comparable to the TA muscle 
from a wild-type C57BL/10 mouse. (B) Maximal 
numbers of human-dystrophin–positive fibers in TA 
muscles of mdx mice injected with either hSM-MSCs 
or pCMV-dystrophin. In three mice, ET was applied 
after plasmid DNA injection. Animals were assayed 
for human-dystrophin expression at 4 wk after injections. 
For each treatment group, three TA muscles were serially 
cross sectioned and stained for human dystrophin. The 
sections containing the highest number of human-
dystrophin–positive fibers were selected. Data are 
mean   SD of maximal numbers of human-dystrophin–
positive fibers per treatment group. (C) Percentage of 
CN human-dystrophin–positive fibers. We observed 
no significant difference comparing the three methods 
of dystrophin delivery. (D) Real-time Q–RT-PCR for 
mouse MGF normalized for mouse/human  -actin. The 
expression levels of mouse MGF in mdx TA muscles 
injected with hSM-MSCs were significantly higher 
(P   0.05) than those found in mdx TA muscles injected 
with pCMV-dystrophin (with or without ET), with PBS, 
or with pCMV-LacZ. Normal TA muscles were from 
three age-matched C57BL/10 mice.T
h
e
 
J
o
u
r
n
a
l
 
o
f
 
C
e
l
l
 
B
i
o
l
o
g
y
916 The Journal of Cell Biology | Volume 160, Number 6, 2003
1994; Yablonka-Reuveni and Rivera, 1994). Our findings
suggest that hSM-MSCs undergo a multistep differentiation
process, which comprises proliferation, commitment to the
myogenic lineage, and eventual terminal maturation and fu-
sion. These kinetics of muscle differentiation appear to be
similar to those of BM cells, since it was reported that myo-
blasts injected into regenerating TA muscle fused into mus-
cle fibers within 5 d, whereas BM cells required at least 2 wk
for integration into muscle fibers (Ferrari et al., 1998).
hSM-MSCs can contribute to functional satellite cells
The number of satellite cells decreases with age, and this pro-
gressive decline is dramatically accelerated in DMD. The de-
pletion of the satellite cell pool, with consequent irreversible
muscle degeneration, is believed to be responsible for termi-
nal muscle failure in DMD (Cossu and Mavilio, 2000). The
ability of implanted stem cells to replenish the satellite cell
compartment may ensure long term efficacy by restoring the
regeneration potential necessary for muscle tissue homeosta-
sis and repair. The persistence as quiescent satellite cells has
been reported with muscle cells (Yao and Kurachi, 1993;
Asakura et al., 2002; Qu-Petersen et al., 2002) and recently
with BM cells (LaBarge and Blau, 2002). In the present
study, we have demonstrated that a small population of the
implanted hSM-MSCs persisted as functional satellite cells in
muscle tissues for over 6 mo. Human mononuclear cells re-
covered from first recipient mice displayed in vitro pheno-
typic and functional properties of primary myoblasts and re-
tained their myogenic capacity into second recipient mice.
Since conversion of syncytial myofibers to mononucleated
myoblasts has been described in mammals under specific
conditions (Odelberg et al., 2000), we cannot exclude that
recovered human mononuclear cells might have derived from
disassembly and dedifferentiation of human myonuclei.
Recently, it has been demonstrated that adult skeletal muscle
contains a population of stem cells distinct from satellite cells
located outside of the muscle fiber basal lamina (Asakura et al.,
2002). As shown in Fig. 4 A, we detected human mononucle-
ated cells lying outside of the basal lamina. The phenotype and
biology of these cells are currently under investigation.
Rescue of peculiar pathophysiologic features of 
dystrophic mdx muscle
The pathologic traits of the dystrophic mdx muscle include
the absence of dystrophin protein and a high number of CN
fibers (Gillis, 1999). Like dystrophin complementation via
gene transfer, hSM-MSC transplantation resulted in restora-
tion of dystrophin at the sarcolemma of muscle fibers and in
a decrease of centronucleation in human-dystrophin–positive
myofibers. In addition, hSM-MSCs rescued, at least in part,
the capacity of mdx mouse muscle cells to produce MGF, a
critical factor controlling local muscle maintenance and re-
pair (Yang et al., 1996) not detectable in dystrophic mdx
muscles (Goldspink, 1999; Yang and Goldspink, 2002).
Dystrophin, possibly involved in mechanotransduction
mechanisms, may play a role in the regulation of MGF ex-
pression in muscle fibers in response to mechanical stimuli
(Goldspink, 1999). The expression of a full-length human
dystrophin by plasmid DNA delivery failed to rescue mouse
MGF. However, the experimental protocols may explain, at
least in part, this discrepancy. Cell implantation was local-
ized, whereas plasmid injections were distributed along the
muscle length. Possibly, in the first case a small number of
fibers were expressing sufficient levels of dystrophin to re-
cover mouse MGF expression. In the second case, a larger
number of fibers were expressing lower amounts, not suffi-
cient to reach the threshold needed for the correction of this
specific disorder. Additionally, one must bear in mind that
the correction of the molecular defect of DMD muscle with
a functional dystrophin protein may not be curative for sec-
ondary events already established during the course of the
hereditary disorder.
In conclusion, our data provide evidence that hSM-
MSCs cannot only correct the initial molecular defect in
mdx mice but also restore expression of mouse MGF, a
molecule involved in maintenance and repair of skeletal
muscle (Goldspink, 1999). These findings further support
the potential of cellular therapeutics in patients with dystro-
phic muscle disorders.
Materials and methods
MSC isolation and culture
Random biopsies of SM (wet weight 10–50 mg) were obtained aseptically
from the knee joints of human donors of various ages (mean 48 yr, range
18–83 yr) within 12 h postmortem. MSCs were isolated and expanded in
monolayer on plastic in growth medium (DME [Life Technologies] con-
taining 10% FBS [BioWhittaker] and antibiotics [Life Technologies]) as de-
scribed previously (De Bari et al., 2001). At passage 3, aliquots of cells
were cryopreserved in liquid nitrogen, thawed after variable times (range
3–36 mo), replated, and expanded. For all experiments, we used SM-MSCs
between passages 3 and 10.
Adenovirus transduction
The replication-deficient recombinant AdCMV-LacZ and the empty back-
bone adenovirus were gifts from The Center for Transgene Technology and
Gene Therapy (Leuven, Belgium). For transduction, cells were replated in
growth medium after addition of the virus at 10 multiplicity of infection.
The next day, the virus supernatant was removed, and the cells were
washed with several changes of medium. 5 d later, cells were harvested for
the in vivo myogenesis assay. The efficiency of transduction was  50%.
Animals and transplant procedure
Animal experimentation protocols were approved by the local ethics com-
mittee. 8-wk-old female NMRI nu
 /  mice were used for the in vivo model
of muscle regeneration. 25  l of 10  M CTX (Latoxan) were injected in the
TA muscle. The day after, 5   10
5 hSM-MSCs suspended in 25  l PBS
were administered (single-point injection) into the same TA muscle. For
systemic injections, 5   10
6 hSM-MSCs in 250  l DME were infused into
the bloodstream of a tail vein.
Dystrophin-deficient mdx mice (C57BL/10ScSn DMD
mdx/J) were pur-
chased from Jackson ImmunoResearch Laboratories. 2-mo-old mice were
used for all experiments. Transplantation was performed by single-point
injection of 10
6 hSM-MSCs in 50  l PBS into the right TA muscle. The left
TA muscle served as internal control receiving PBS. Recipient mice were
immunosuppressed with FK506 (Fujisawa Pharmaceutical Co. Ltd.) admin-
istered intraperitoneally at the dose of 2.5 mg/kg per day (Kinoshita et al.,
1994) from the day of transplantation until the animals were killed 4 wk af-
ter transplantation.
DNA injection and electric pulse delivery
pTG11025 plasmid containing full-length human dystrophin driven by the
CMV promoter (Braun et al., 2000) was a gift from S. Braun (Transgene,
Strasbourg, France). Six mdx mice were anesthetized, and 50  g of plasmid
DNA in 50  l of 0.9% NaCl was injected percutaneously into the right TA
muscle in 5–10 different sites (5–10  l per site). Sham control injections
were done with pCMV-LacZ or PBS. Immediately after DNA administration,
transcutaneous electric pulses were applied to the hindlimbs of three miceT
h
e
 
J
o
u
r
n
a
l
 
o
f
 
C
e
l
l
 
B
i
o
l
o
g
y
 Synovial cells for muscle repair | De Bari et al. 917
as described previously (Vilquin et al., 2001). The animals were immuno-
suppressed with FK506 and killed 4 wk after plasmid DNA injection.
Myoblast isolation and transplantation
Primary myoblasts were isolated from TA muscles of six nude mice (14 mo
of age) transplanted with hSM-MSCs 6 mo earlier as described previously
(Ferrari et al., 1998). Dissociated single cells were plated on plastic Petri
dishes and maintained for 2 h at 37 C in growth medium to allow attach-
ment of fibroblasts. Nonadherent cells were collected and plated on gela-
tin-coated culture plates in DME containing 20% FBS and antibiotics. Dif-
ferentiation to myotubes was induced by exposing confluent myoblast
culture to DME containing 2% horse serum (Life Technologies) for 48 h. At
70% confluence, myoblasts were released with trypsin and implanted into
regenerating TA muscles. Since the expanded myoblast population con-
tained both mouse and human cells, we used 3   10
6 cells in 60  l PBS
per injection.
Tissue processing
Mice were killed by cervical dislocation, and TA muscles were excised.
For total RNA extraction, TA muscles were homogenized in TRIzol (Life
Technologies). For histology, histochemistry, and ISH, unless differently
stated, they were either fixed overnight at 4 C in 10% neutral buffered for-
malin, embedded in paraffin, and sectioned at 5  m, or cryoembedded
and sectioned at 10  m. For staining for human  2M, specimens were
fixed with 2% glutaraldehyde in 0.05 M cacodylate buffer (pH 7.3) at 4 C
for 60 min, embedded in paraffin, and sectioned at 7  m. Sections were
mounted on poly-L-lysine–coated glass slides and Thermanox coverslips
(Electron Microscopy Sciences) for light microscopy and TEM, respec-
tively. TA muscles from mdx mice were divided transversely into two
equal parts, of which one was used for total RNA extraction and the other
to make cryosections.
Histochemistry
Whole mount X-gal staining of TA muscles was performed overnight at 30 C
according to the standard method. Muscles were then embedded in paraffin
and sectioned at 7  m to observe LacZ expression at the cellular level.
To perform immunostaining for human  2M, sections were deparaf-
finized and blocked with sheep anti–mouse Ig (Chemicon). Endogenous
peroxidase was quenched with 0.5% H2O2 in methanol. Sections were in-
cubated for 1 h with a mouse mAb specific to human  2M (BD Bio-
sciences) diluted 1:50 in PBS. For light microscopy, immunoreactivity was
detected using the peroxidase-based EnVision
TM System (Dako) using DAB
as a chromogenic substrate and Mayer’s hematoxylin to counterstain nu-
clei. For TEM, immunoreactivity was detected using a silver-enhanced
preembedding colloidal gold immunohistochemistry system (Aurion). After
immunolabeling, sections were postfixed in 2% osmium tetroxide, stained
with 2% uranyl acetate in 10% acetone, dehydrated, and embedded on
the plastic coverslip in araldite according to the “Pop-Off technique.” Ul-
trathin sections (0.2  m) were mounted on 0.7% formvar-coated grids,
stained with uranyl acetate and lead citrate, and examined with a Philips
EM 208 transmission electron microscope.
For double immunofluorescence (IF) staining, cryostat sections were
fixed with 4% PFA, blocked with sheep anti–mouse Ig, and incubated
overnight at 4 C with 10  g/ml rabbit antilaminin polyclonal antibody (In-
noGenex) and mouse anti–human  2M mAb diluted 1:50. The secondary
antibodies were Cy3-conjugated goat anti–rabbit IgG (Jackson ImmunoRe-
search Laboratories) and Cy2-conjugated goat anti–mouse IgG (H L)
(Kirkegaard & Perry Laboratories). To detect human dystrophin, we used
the mAb NCL-DYS3 (Novocastra Laboratories) following the manufac-
turer’s protocol, with Cy3-conjugated goat anti–mouse IgG (Jackson Im-
munoResearch Laboratories) as secondary antibody. Slides were mounted
with Mowiol containing DAPI. Tissue and Ig isotype negative controls
were included.
In situ hybridization
ISH for human Alu genomic repeats was performed as described else-
where (Dell’Accio et al., 2001). Slides were mounted with Mowiol con-
taining DAPI. For FISH, mouse centromeric probe was generated by PCR
using the following primers: forward, 5 -GGAAAATGATAAAAACCA-
CACTG-3  and reverse, 5 -TGTTTCTCATTGTAACTCATTGAT-3 . The hu-
man probe was generated from BAC DNA (RPCI-373M8) containing
CEN18 sequences. Labeling of the human CEN18 DNA and the mouse
centromeric PCR product with fluorescein-dUTP and lissamine-dUTP, re-
spectively, was performed using the BioNick™ Labeling System kit (Life
Technologies). Cryostat sections were treated with pepsin, fixed in 1%
acid-free formaldehyde solution in PBS, washed with PBS, dehydrated,
and air dried. Chromosomes were denatured by incubating the slides at
72 C in a 70% formamide/2  SSC solution and dehydrated through an
ice-cold ethanol series. Probes were denatured in hybridization mixture
(50% formamide, 2  SSC, 10% dextran-sulfate) for 5 min at 75 C and ap-
plied on the slides, which were incubated overnight at 37 C. The next day,
slides were washed 1 min in 0.4  SSC/0.3% NP-40 at 73 C, 1 min in 2 
SSC/0.1% NP-40 at RT, and 5 min in 4T (4  SSC, 0.05% Tween 20, pH
7.0) at RT. Slides were dehydrated and mounted with antifade medium
(Vectashield; Vector Laboratories) containing DAPI.
RT-PCR
Total RNA was isolated using TRIzol. After DNase treatment, cDNAs were
obtained by reverse transcription of 2  g of total RNA (Thermoscript; Life
Technologies) using oligo(dT)20 as primer. SQ-PCR was performed as de-
scribed previously (De Bari et al., 2001). Gene expression of human cells
within muscle tissues was evaluated using primers specific for human
cDNAs. When mouse/human chimeric samples were equalized for the ex-
pression of human  -actin, control mouse samples with no human cells
were normalized to the mouse/human chimeric sample of the series with
the highest mouse/human  -actin. In the mouse/human chimeric samples,
the molar ratio of human over mouse  -actin mRNA was  0.01 as deter-
mined by Q–RT-PCR. Therefore, in Figs. 1 E and 2 A, after normalization
for human  -actin at 25 cycles, the 18 cycles performed for mouse/human
 -actin were optimal to show that the mouse controls contained at least as
much cDNA template as the most concentrated of the experimental
mouse/human samples but not sufficient to reach detection levels of  -actin
in the human reference samples. For MGF, the reverse primer was located
within the insert that differentiates MGF from insulin-like growth factor-I
(Yang et al., 1996) (sequence data available from GenBank/EMBL/DDBJ
under accession no. U40870 for human cDNA, and NM_010512 for
mouse cDNA). Sequencing of the PCR product confirmed the specificity of
the primers for mouse MGF. Real-time Q-PCR was performed using the
ABI PRISM 7700 detection system (Taqman; Applied Biosystems). The se-
quences of the primers and the expected sizes of the amplification prod-
ucts are listed in the Table S1 (available at http://www.jcb.org/cgi/content/
full/jcb.200212064/DC1).
Statistics
An investigator, unaware of the treatment group, analyzed a minimum of
300 fibers per mdx TA muscle. Results are mean   SD. Data were ana-
lyzed using the Student’s t test for the comparison of the CN muscle fibers,
and the one way repeated measures ANOVA followed by multiple com-
parisons with the Student-Newman-Keuls method to compare the values of
MGF expression. P   0.05 was significant.
Online supplemental material
Fig. S1 shows that the in vivo myogenic potential of hSM-MSCs was repro-
ducible, regardless of cell storage in liquid nitrogen or donor age, within
the ranges examined and was inherent to individual cell clones of multipo-
tent SM-MSCs. Fig. S2 shows that CTX treatment was not required for mus-
cle differentiation of hSM-MSCs and that differentiation of locally im-
planted hSM-MSCs to skeletal muscle was a tissue-specific event with no
detectable heterotopic tissue formation. In Table S1, the sequences of the
primers and the expected sizes of the amplification products are listed. All
supplemental material is available at http://www.jcb.org/cgi/content/full/
jcb.200212064/DC1.
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